ArticleOncotarget2018

PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via upregulation of YAP1 expression.

Jai-Nien Tung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.